Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
Supply increase to help meet growing global demand
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Subscribe To Our Newsletter & Stay Updated
